Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Suspended 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Sarcoma, Kaposi 2Sarcoma 2Ovarian Neoplasms 2Multiple Myeloma 2Melanoma 2Hemangioma, Capillary 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Ulcer 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Skin Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Lymphatic Metastasis 1Liver Neoplasms 1Fallopian Tube Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 137Nivolumab 116Ipilimumab 68Cyclophosphamide 33Specimen Handling 31Magnetic Resonance Spectroscopy 28trametinib 23binimetinib 22fludarabine 21Interleukin-2 20dabrafenib 19relatlimab 17encorafenib 17Biopsy 17CTLA-4 Antigen 16cemiplimab 15atezolizumab 15aldesleukin 15Radiosurgery 15fludarabine phosphate 14Opdualag 14Radiotherapy 11lenvatinib 10Blood Specimen Collection 10lifileucel 9Paclitaxel 8Cisplatin 8Bevacizumab 8spartalizumab 7cobimetinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Propranolol × 1 year × Clear all
NCT05968690 2025-09-18

Naltrexone and Propranolol Combined With Immunotherapy

Rutgers, The State University of New Jersey

Phase 1 Recruiting
12 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT03384836 2025-07-02

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

Roswell Park Cancer Institute

Phase 1/2 Suspended
47 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡